Bank of New York Mellon Corp Increases Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Bank of New York Mellon Corp lifted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 3.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 123,832 shares of the specialty pharmaceutical company’s stock after acquiring an additional 4,404 shares during the period. Bank of New York Mellon Corp owned 0.59% of ANI Pharmaceuticals worth $6,845,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ANIP. KBC Group NV grew its position in ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after buying an additional 600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after buying an additional 579 shares during the last quarter. HighTower Advisors LLC purchased a new position in ANI Pharmaceuticals in the 3rd quarter valued at $222,000. China Universal Asset Management Co. Ltd. grew its position in ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock valued at $246,000 after buying an additional 412 shares during the last quarter. Finally, Hohimer Wealth Management LLC purchased a new position in ANI Pharmaceuticals in the 3rd quarter valued at $264,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 400 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the transaction, the vice president now owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. The trade was a 0.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the transaction, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at $4,131,164.80. The trade was a 1.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,700 shares of company stock valued at $610,201 in the last 90 days. 12.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ANIP shares. Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research report on Friday. They issued a “buy” rating and a $80.00 price objective on the stock. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. HC Wainwright reissued a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price for the company. Finally, JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a report on Wednesday. They issued an “overweight” rating and a $85.00 target price for the company. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $79.75.

ANI Pharmaceuticals Trading Up 1.7 %

NASDAQ:ANIP opened at $62.49 on Friday. The company has a market capitalization of $1.36 billion, a PE ratio of -113.62 and a beta of 0.62. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.81. The stock has a fifty day simple moving average of $58.40 and a 200-day simple moving average of $58.09.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.